studies

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 829A
strategies to improve post-LT survival of patients with cirrhosis
with history of pre-transplant acute kidney injury.
Disclosures:
The following authors have nothing to disclose: Paul S. Fitzmorris, Kirk B. Russ,
Donny Kakati, Ashwani Singal
Disclosures:
Zobair M. Younossi - Advisory Committees or Review Panels: Salix, Janssen,
Vertex; Consulting: Gilead, Enterome, Coneatus
Aijaz Ahmed - Consulting: Bristol-Myers Squibb, Gilead Sciences Inc., Roche,
AbbVie, Salix Pharmaceuticals, Janssen pharmaceuticals, Vertex Pharmaceuticals,
Three Rivers Pharmaceuticals; Grant/Research Support: Gilead Sciences
Inc.
The following authors have nothing to disclose: Maria Aguilar, Edward W. Holt,
Taft Bhuket, Benny Liu, Robert J. Wong
1253
Renal Function Recovery and Outcomes after Liver
Transplantation Alone among Patients with Pre-Transplant
Acute Kidney Injury
Paul S. Fitzmorris 1 , Kirk B. Russ 1 , Donny Kakati 1 , Ashwani Singal
2 ; 1 Internal medicine, University of Alabama at Birmingham,
Birmingham, AL; 2 Gastroenterology and Hepatology, University of
Alabama at Birmingham, Birmingham, AL
Purpose: Data on recovery of renal function recovery after liver
transplantation (LT) alone are controversial. Methods: From an
ongoing prospective study to define urine or serum biomarkers
predictive of renal function recovery after LT, high risk patients
with history of acute kidney injury (AKI) while waiting for LT
were prospectively followed for renal function recovery at 6 mo.
and for patient survival at 1 yr. after LT. Glomerular filtration
rate was estimated using the modified diet in renal disease-6
(MDRD-6) equation. Results: Of 109 patients with pre-LT AKI,
52 successfully received LT. After excluding 3 with simultaneous
kidney and 2 with lack of pre-transplant data, 47 (38 with
1, 6 with 2, and 3 with 3 episodes of AKI) receiving LT alone
were reviewed. Of these, 13 were excluded from analysis for
lack of MDRD-6 data at 6 months after LT (n=4), not made up to
6 months after LT (n=5), and death within 6 months of LT (n=4,
1 each due to operative on table, sepsis, pulmonary embolism,
and exploratory laparotomy for hemorrhage). Of remaining 34
patients, 11 with recovery of renal function (improved MDRD-6
by 50% compared to MDRD-6 at LT) differed from 23 who
without recovery of renal function for MDRD-6 at LT (28±15
vs. 60±30, p=0.002) and length of stay after LT (15±6 d vs.
8±3 d, p=0.0002) without differences on age at LT, sex comorbidities,
pre-existent chronic kidney disease, and number of
AKI episodes prior to LT. Of 25 patients with MDRD-6